Charles River Laboratories International Inc. (CRL) has been in the news recently due to a variety of developments. The company's Executive Vice President, Joseph Laplume, and Director George Massaro both sold shares in the company, while StockNews.com upgraded the company to a 'Buy'. The company's First Quarter 2024 earnings reported a revenue beat but EPS lag. CRL also opened a RightSource Lab in Stevenage. Among other transactions, Jackson Square Partners LLC purchased over 80,000 CRL shares while others reduced their stakes, such as BNP Paribas Financial Markets and Curi Wealth Management LLC.
CRL's stock forecast and price target for 2024 were revealed, and the company made a strategic update in a lawsuit. Furthermore, CRL has seen some trends in international revenue, and it has lowered the price target by certain analysts. The organization remains committed to corporate citizenship, as seen in its 2023 report, and maintains a healthy balance sheet. Moreover, the firm continues to invest in reducing its reliance on animal testing and improving its technology-driven capabilities. Notably, earnings for Q1 and Full Year 2022 exceeded expectations.
Charles River Laboratories International CRL News Analytics from Wed, 08 Nov 2023 08:00:00 GMT to Sun, 19 May 2024 09:46:11 GMT - Rating 5 - Innovation 6 - Information 7 - Rumor 3
